While the methyltransferase has been associated with oncogenic properties in, e.g., lung- and prostate cancer [60,61], glioblastoma [43], or lymphoma [1], tumor-suppressive EZH2 activities have been revealed for T-cell acute lymphoblastic leukemia [62], clear cell renal carcinoma [63], or colorectal cancer [44]. This evidence concerns the gene EZH2 and clear cell renal carcinoma.